BFEC
PETX

Benjamin F. Edwards & Company’s Aratana Therapeutics, Inc. PETX Stock Holding History

Benjamin F. Edwards & Company’s Portfolio PETX Stock Details PETX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-3,000
Closed -$25K – 1279
2015
Q3 		$25K Buy
+3,000
New +$50.8K 0.01% 666

Other funds holding PETX

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Benjamin F. Edwards & Company's PETX Position: Q4 2015 in Review

Benjamin F. Edwards & Company sold out of Aratana Therapeutics, Inc. (PETX) in Q4 2015, closing a stake of 3,000 shares — an estimated $25K sold.

Benjamin F. Edwards & Company first reported a position in PETX in Q3 2015 and held it in 1 quarter. The position peaked at $25K in Q3 2015. 98 funds tracked by Wall St. Rank hold PETX as of Q4 2015.

  • Benjamin F. Edwards & Company reported no remaining Aratana Therapeutics, Inc. position as of Q4 2015 after selling out during the quarter.
  • Benjamin F. Edwards & Company sold 3,000 Aratana Therapeutics, Inc. shares in Q4 2015, an estimated $25K.
  • Benjamin F. Edwards & Company first reported a position in Aratana Therapeutics, Inc. in Q3 2015 and held it in 1 quarter.
  • Benjamin F. Edwards & Company's Aratana Therapeutics, Inc. position peaked at $25K in Q3 2015.
  • 98 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q4 2015.

Based on Benjamin F. Edwards & Company's 13F filing for Q4 2015, filed 12 Jan 2016.